P21
Also known as: CNTF-derived peptide · neuropoietin-related peptide
A small peptide derived from a neurotrophic-cytokine framework, characterised in academic research for hippocampal neurogenesis induction and anti-neuroinflammatory effects in models of cognitive ageing and Alzheimer-type pathology.
P21 (Pep21) is a CNTF-derived peptide that induces adult hippocampal neurogenesis; studied in Alzheimer's mouse models — preclinical evidence only.
Evidence tier: C — preclinical / mechanistic evidence only
- Category
- Neurogenesis
- Half-life
- Pharmacodynamic effects on neurogenesis extend across weeks despite shorter plasma exposure
Section 1
Overview
P21 is a small synthetic peptide engineered from a region of the neurotrophic-cytokine family — the same superfamily that includes ciliary neurotrophic factor (CNTF) and the leukaemia inhibitory factor — designed to retain the pro-neurogenic activity of the full protein while losing the broader cytokine effects that would otherwise dominate the systemic response.
The molecule has been characterised in academic research as one of the few peptide candidates capable of measurably inducing hippocampal neurogenesis in adult animals — generating new dentate gyrus neurons from quiescent neural stem cells. The endpoint matters because adult hippocampal neurogenesis is one of the few demonstrated routes by which the adult brain produces structurally new processing capacity, and its rate declines with age and with chronic stress.
P21 also shows anti-neuroinflammatory effects in cell-culture and animal models, attenuating microglial activation in response to amyloid-beta exposure and similar inflammatory triggers. The compound is studied in models of cognitive ageing and Alzheimer-type pathology where neurogenic decline and neuroinflammation are both implicated.
Section 2
Discovery & History
- Developed in academic research as part of a programme to derive smaller, more drug-like fragments from the cytokine-family neurotrophic factors that had themselves proven impractical as therapeutics due to molecular size and pleiotropic effects.
- Subject to a peer-reviewed preclinical literature from the early 2010s onwards, with the strongest data coming from murine models of cognitive ageing and Alzheimer-type pathology.
- Has not progressed to clinical-trial registration in any jurisdiction. No human safety or efficacy data is publicly available.
- Remains a research peptide used as a tool for studying adult neurogenesis and neuroinflammation pharmacology.
Section 3
Mechanism of Action
- 1Promotion of adult hippocampal neurogenesis — induction of neural stem cell proliferation in the subgranular zone of the dentate gyrus, followed by enhanced survival and integration of newly differentiated neurons into the existing hippocampal circuit.
- 2Modulation of the JAK-STAT signalling cascade downstream of the cytokine-receptor framework the peptide derives from — specifically the LIF/CNTF receptor complex — without producing the broader systemic cytokine effects that limited the therapeutic use of the parent molecules.
- 3Anti-neuroinflammatory effects via attenuation of microglial activation, reduction of pro-inflammatory cytokine release, and shift of microglia toward the M2 (resolution) phenotype — providing a mechanistic angle complementary to the neurogenic effect.
- 4Indirect cognitive effects through restoration of neurogenic capacity in aged or pathological brain states where baseline dentate-gyrus neurogenesis is depressed — the mechanistic root of the improved learning-task performance in aged-model cohorts.
- 5Reported reduction of amyloid-beta-induced neuronal injury in Alzheimer-model preparations, partly via the anti-inflammatory mechanism and partly via direct neurotrophic support of stressed neurons.
- 6Restoration of long-term potentiation (LTP) magnitude in aged-brain hippocampal slice preparations, providing a cellular-level cognitive-correlate substrate for the observed behavioural improvements.
- 7Preservation of dendritic spine density in the hippocampus of aged and disease-model animals, indicating a synaptic-integrity contribution alongside the neurogenic effect.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Induction of measurable adult hippocampal neurogenesis in aged-mouse models in published research — quantified via BrdU-positive dentate-gyrus neuron counts and DCX-positive neurogenic markers.
- 2Improved performance on hippocampus-dependent learning tasks (Morris water maze, contextual fear conditioning, novel-object recognition) in cognitively impaired aged-mouse and disease-model cohorts.
- 3Anti-neuroinflammatory effects in models of Alzheimer-type pathology — reduced microglial activation, decreased pro-inflammatory cytokine expression, improved neuronal survival.
- 4Restoration of synaptic plasticity markers (LTP magnitude, dendritic spine density, PSD-95 expression) in aged-brain preparations.
- 5Distinct mechanism from the BDNF-inducer family — useful as a complementary research tool for interrogating the neurogenesis-cognition axis independently of neurotrophin-driven synaptic-stabilisation effects.
- 6Reported preservation of cognitive endpoints in Alzheimer's-disease mouse models, providing a preclinical scaffold for the neurodegenerative-disease research positioning.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / intraperitoneal (research) | Microgram-range doses in animal protocols | Daily during a study course | Variable; chronic protocols of several weeks have been examined in mouse research |
Note: No validated human protocol exists. No clinical trials are publicly registered.
Section 6
Administration Routes
- Subcutaneous injection — the primary route in published animal research, providing consistent plasma exposure and reproducible pharmacokinetic characterisation.
- Intraperitoneal administration in some rodent research where high-plasma-peak pharmacology is targeted.
- Intranasal delivery has been explored in mechanistic work but is not the standard route.
- Oral administration has not been validated in published research — the peptide is presumed susceptible to gastrointestinal proteolysis given its size and composition.
Section 7
Safety Profile
Commonly reported
- · Limited safety data — preclinical animal research only, no human pharmacovigilance database exists for the peptide.
- · Generally well-tolerated in the reported animal protocols at studied doses; no observable weight, behaviour, or gross-pathology changes at course lengths of 4–12 weeks.
- · No documented dependence, tolerance, or withdrawal phenomena in the published animal work.
- · Injection-site reactions at subcutaneous administration sites reported at low frequency and without clinical consequence.
Rare / theoretical
- · Theoretical concerns relating to chronic JAK-STAT modulation, which is implicated in some oncogenic pathways when persistently activated — the single most significant theoretical concern for chronic human use.
- · Long-term toxicology data is not publicly available — the compound has not been through a GLP toxicology package.
- · Pleiotropic cytokine-family pharmacology — even with the smaller peptide, off-target signalling on non-CNS tissues expressing the receptor cannot be ruled out.
- · No reproductive or developmental toxicology data — treat as absolutely contraindicated in reproductive-context research use.
Contraindications
- · Not authorised for human use in any jurisdiction
- · Theoretical contraindication in subjects with active or historic malignancy via the JAK-STAT mechanism
- · No data in pregnancy, lactation, or paediatric contexts
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine. Research chemical for laboratory and preclinical use only.
European Union
Not approved by the EMA. No clinical authorisation in any major EU jurisdiction.
Section 9
Clinical Studies Summary
P21 induces adult hippocampal neurogenesis in aged mice
Chronic subcutaneous P21 administration over 8 weeks produced measurable increases in dentate-gyrus BrdU-positive neuron counts, DCX-positive neurogenic markers, and mature-neuron differentiation in aged C57BL/6 mice versus age-matched vehicle controls, with corresponding improvements on hippocampus-dependent learning tasks. The flagship preclinical demonstration of the compound's neurogenic effect.
P21 attenuates amyloid-beta induced neuroinflammation
Behavioural and molecular study demonstrating reduction of microglial activation markers, decreased pro-inflammatory cytokine release, and preserved cognitive performance in APP/PS1 Alzheimer-model mouse brains receiving P21 administration during the pathology-progression window, extending the mechanistic evidence base into neuroinflammatory disease models.
Cognitive recovery in Alzheimer's mouse models with P21 treatment
Extended treatment study in transgenic mouse models of Alzheimer-type pathology reporting partial restoration of spatial and recognition memory performance (Morris water maze, novel-object recognition) following chronic P21 administration, alongside molecular evidence of preserved synaptic-plasticity markers.
P21 in models of cognitive ageing
Behavioural pharmacology study in aged Wistar rats reporting improved contextual fear conditioning and Y-maze performance following a 6-week P21 course, with post-mortem analysis showing preserved dendritic spine density and increased synaptophysin expression in the hippocampus of treated animals.
P21 mechanism-of-action characterisation
Molecular pharmacology study characterising P21's action on the JAK-STAT signalling cascade downstream of the LIF/CNTF receptor complex, providing the mechanistic scaffold that distinguishes P21 from BDNF-inducing peptides while identifying convergent effects on cognitive-relevant plasticity pathways downstream.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing P21 for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain P21 from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.